InvestSMART

Racura Oncology Ltd (ASX:RAC)

ALERT: Price-sensitive ASX Announcement for RAC
Current share price for RAC : $2.160 -0.15 (-6.49%)+
Announcement
Release
25 Jun 2026 8:55AM
Price at Release
$2.310
Full Release
download
Summary
Racura Oncology Ltd has announced the treatment of the first patient in the HARNESS-1 Phase 1 clinical trial, which evaluates the drug RC220 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer (NSCLC). The primary objective is to assess the safety and determine the maximum tolerated dose of RC220. The trial is being conducted at Monash Health in Victoria, Australia, under the leadership of Associate Professor Surein Arulananda. The treatment of the first patient marks a significant milestone in addressing the challenge of resistance to current targeted therapies for this patient group.
Key Points
  • First patient treated in HARNESS-1 Phase 1 trial with RC220.
  • RC220 evaluated in combination with osimertinib for EGFR-mutant NSCLC.
  • Trial aims to determine the safety and maximum tolerated dose of RC220.
  • Conducted at Monash Health in Victoria, Australia.
  • Significant milestone in addressing resistance to targeted therapies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.